Change over period: —
NSE · PANACEABIO
PANACEA BIOT
-41.3% from the 52-week high · +20.4% above the low
Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm manufactures a range of paediatric vaccines, including hexavalent vaccine, EasySixTM; pentavalent vaccine, Easyfive- TT and bivalent oral polio vaccine in India and market the same in India, as well as in international markets. The Company’s products include EasySix, Easyfive-TT, Easyfour-TT, EasyFourPol and Bi-OPV. Its pipeline candidates include BPBC, Hepatitis A, Covid-19 VoC mAb, NuVac-23, NuCoVac-11, Td and DengiAll. The firm is in the process of initiating phase III clinical trials for NucoVac-11, DengiAll and Td vaccines. Its operations are spread across different geographies in India. The firm has two manufacturing facilities located in Lalru, Punjab and Baddi, Himachal Pradesh, and two research and development (R&D) centers in Lalru, Punjab and New Delhi.
The short version. PANACEA BIOT reported revenue of ₹190 crore for Sep 2026, up 34.8% from a year earlier. Net profit was ₹12 crore. Return on equity was -0.6% in Mar 2026. Promoter holding was 72.48% in Sep 2026, down 0.01 points over 8 quarters.
1 · The price
How has the stock traded?
PANACEA BIOT trades 41.3% below its 52-week high and 20.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹190 cr.
16.0 pts higher than a year earlier.
Revenue compounded at 8.7% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 190 | 200 | 167 | 165 | 141 | 167 | 133 | 163 |
| Net profit | 12 | 2 | 1 | 4 | -14 | 4 | -2 | 5 |
| Net margin % | 6.1 | 1.2 | 0.3 | 2.4 | -9.9 | 2.4 | -1.4 | 2.8 |
| EPS (₹) | 1.9 | 0.38 | 0.08 | 0.65 | -2.27 | 0.66 | -0.31 | 0.74 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 640 | 559 | 559 | 460 | 661 | 625 | 544 |
| Net profit | -5 | -8 | -1 | -34 | 1078 | -148 | -194 |
| Net margin % | -0.8 | -1.5 | -0.2 | -7.3 | 163.0 | -23.6 | -35.7 |
| EPS (₹) | -0.88 | -1.37 | -0.19 | -5.51 | 175.98 | -24.11 | -31.72 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -0.6% in Mar 2026; debt to equity is 0.03.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -0.6 | -1.0 | -0.1 | -4.0 |
| Return on capital % | -0.1 | -0.4 | 0.5 | 1.8 |
| EBITDA margin % | 4.8 | 5.3 | 7.1 | 11.0 |
| Net margin % | -0.8 | -1.4 | -0.2 | -6.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 8.7% | 0.7% |
| Profit CAGR | -45.8% | -48.5% |
4 · The owners
Who holds it, and are they adding?
Down 0.01 pts over 8 quarters.
Up 2.37 pts over 8 quarters.
Up 1.3 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.49 | 72.48 | 72.48 | 72.48 | 72.48 | 72.48 | 72.48 | 72.48 | -0.01 |
| FII | 0.38 | 1.16 | 0.78 | 1.06 | 1.36 | 1.6 | 2.31 | 2.75 | +2.37 |
| DII | 1.17 | 1.49 | 1.52 | 1.81 | 1.85 | 1.97 | 2.25 | 2.47 | +1.3 |
| Public | 25.97 | 24.86 | 25.22 | 24.66 | 24.3 | 23.96 | 22.96 | 22.3 | -3.67 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.03% of NAV
- Bandhan BSE Healthcare Index Fund0.03% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for PANACEA BIOT are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about PANACEA BIOT
What is the PANACEA BIOT share price?
PANACEA BIOT (PANACEABIO) last closed at ₹352.85, down 1.04% on the day. Its 52-week range is ₹296.05 to ₹607.75.
What is the market cap of PANACEA BIOT?
PANACEA BIOT has a market capitalisation of about ₹2,169 crore.
How are PANACEA BIOT's latest results?
PANACEA BIOT reported revenue of ₹190 crore for Sep 2026, up 34.8% from a year earlier. Net profit was ₹12 crore. Return on equity was -0.6% in Mar 2026. Promoter holding was 72.48% in Sep 2026, down 0.01 points over 8 quarters.
Who owns PANACEA BIOT?
As of Sep 2026, shareholding was: Promoter 72.48%, FII 2.75%, DII 2.47%, Public 22.3%.
How many mutual funds hold PANACEA BIOT?
2 mutual fund schemes held PANACEA BIOT in October 2026. That compares with 2 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.